Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + dexamethasone in relapsed/refractory multiple myeloma (China, phase 3)
CTR20160670Phase 3Active
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Sep 2016
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide in multiple myeloma (MM), sponsored by Simcere Pharmaceutical Group. Started Sep 2016; status: active.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20160670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160670.